רמוואב
neopharm scientific ltd - catumaxomab 100 mcg/ml - concentrate for solution for infusion - catumaxomab - intraperitoneal treatment of malignant ascites in patients with epcam-positive carcinomas where standard therapy is not available or no longer feasible.
ארביטוקס 5 מגמל
merck serono ltd - cetuximab - תמיסה לאינפוזיה - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, kras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease
וקטיביקס 20 מגמל
amgen europe b.v. - panitumumab - תרכיז להכנת תמיסה לאינפוזיה - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type kras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type kras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
ברפטובי 75 מג
medison pharma ltd - encorafenib - קפסולות ג'לטין קשיחות - encorafenib 75 mg - encorafenib